Proteins & Peptides

Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end). This protein corresponds to SARS-CoV-2 Variant B.1.1.7 originally discovered in the United Kingdom, and contains mutations D3L, R203K, G204R, and S235F. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end), plus a C-terminal Avi-tag™ and a C-terminal His-tag. This protein corresponds to SARS-CoV-2 Variant P.1 originally discovered in Brazil and contains the mutation P80R.

Recombinant E. coli CLPP (ATP-dependent Clp protease proteolytic subunit) encompassing amino acids 15-207 (end). This construct contains an N-terminal His-tag (6xHis). The recombinant protein was affinity purified.

Recombinant mouse Angiopoietin-2 encompassing amino acids 19-496. This protein contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag. Affinity purified.

Recombinant human CD19 encompassing amino acids 21-291. This construct contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein was affinity purified.

This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

Recombinant human B cell receptor CD22 encompassing amino acids 20-464. This protein is fused in C-terminal with the Fc fragment of human IgG1 followed by a C-terminal Avi-Tag™. The recombinant protein was affinity purified and labeled with PE.

Recombinant human myeloid cell surface antigen CD33 encompassing amino acids 1-259. This protein is fused in C-terminal with the Fc fragment of human IgG1 followed by a C-terminal Avi-Tag™. The recombinant protein was affinity purified and labeled with PE. 

Recombinant human CD123 encompassing amino acids 20-305 (end). This construct contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein was affinity purified.